- Home
- KOD vs RGNX Comparison
KOD vs RGNX Comparison
Compare KOD & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KOD | RGNX |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 795.5M | 661.2M |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | KOD | RGNX |
|---|---|---|
| Price | $24.09 | $14.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $22.67 | ★ $30.29 |
| AVG Volume (30 Days) | ★ 720.6K | 626.9K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $161,318,000.00 |
| Revenue This Year | N/A | $132.80 |
| Revenue Next Year | N/A | $48.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 91.30 |
| 52 Week Low | $1.92 | $5.04 |
| 52 Week High | $26.21 | $14.24 |
Technical Indicators
Market Signals| Indicator | KOD | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 60.32 | 65.93 |
| Support Level | $21.24 | $12.69 |
| Resistance Level | $24.97 | $14.93 |
| Average True Range (ATR) | 1.70 | 0.80 |
| MACD | -0.16 | 0.12 |
| Stochastic Oscillator | 62.58 | 77.30 |
Price Performance
Historical ComparisonAbout KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.